600422.SS Stock Analysis
60
Avoid
Based on Eyestock quantitative analysis, 600422.SS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
KPC Pharmaceuticals, Inc. engages in the research & development, manufacture, sale, commercial wholesale, and international marketing of drugs. The company is headquartered in Kunming, Yunnan and currently employs 5,719 full-time employees. The company went IPO on 2000-12-06. The firm's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The firm is also engaged in the production of health products and provision of medical services.